Cited by 855Atrial Fibrillation Management and OutcomesAntiplatelet Therapy and Cardiovascular DiseasesBlood Coagulation and Thrombosis Mechanisms

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial Fibrillation

Hansen, Morten L., Sørensen, Rikke, Clausen, Mette T., Fog-Petersen, Marie Louise, Raunsø, Jakob, Gadsbøll, Niels, Gislason, Gunnar H., Folke, Fredrik, Andersen, Søren S., Schramm, Tina K., Abildstrøm, Steen Z., Poulsen, Henrik E., Køber, Lars, Torp-Pedersen, Christian·2010·Archives of Internal Medicine

DOI 10.1001/archinternmed.2010.271

Open this paper in CoChat — free account

Abstract

BACKGROUND: Patients with atrial fibrillation (AF) often require anticoagulation and platelet inhibition, but data are limited on the bleeding risk of combination therapy. METHODS: We performed a cohort study using nationwide registries to identify all Danish patients surviving first-time hospitalization for AF between January 1, 1997, and December 31, 2006, and their posthospital therapy of warfarin, aspirin, clopidogrel, and combinations of these drugs. Cox proportional hazards models were used to estimate risks of nonfatal and fatal bleeding. RESULTS: A total of 82,854 of 118,606 patients (69.9%) surviving AF hospitalization had at least 1 prescription filled for warfarin, aspirin, or clopidogrel after discharge. During mean (SD) follow-up of 3.3 (2.6) years, 13,573 patients (11.4%) experienced a nonfatal or fatal bleeding. The crude incidence rate for bleeding was highest for dual clopidogrel and warfarin therapy (13.9% per patient-year) and triple therapy (15.7% per patient-year). Using warfarin monotherapy as a reference, the hazard ratio (95% confidence interval) for the combined end point was 0.93 (0.88-0.98) for aspirin, 1.06 (0.87-1.29) for clopidogrel, 1.66 (1.34-2.04) for aspirin-clopidogrel, 1.83 (1.72-1.96) for warfarin-aspirin, 3.08 (2.32-3.91) for warfarin-clopidogrel, and 3.70 (2.89-4.76) for warfarin-aspirin-clopidogrel. CONCLUSIONS: In patients with AF, all combinations of warfarin, aspirin, and clopidogrel are associated with increased risk of nonfatal and fatal bleeding. Dual warfarin and clopidogrel therapy and triple therapy carried a more than 3-fold higher risk than did warfarin monotherapy.

Integrity signals

Registry

Crossref · 10.1001/archinternmed.2010.271

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
(1996) · The Lancet · doi:10.1016/s0140-6736(96)09457-3 · Cited by 6,503
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee
Dennis, M. S. (1996) · The Lancet · Cited by 2,728
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102
Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial
(2006) · The Lancet · doi:10.1016/s0140-6736(06)68845-4 · Cited by 1,952
PLACEBO-CONTROLLED, RANDOMISED TRIAL OF WARFARIN AND ASPIRIN FOR PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN CHRONIC ATRIAL FIBRILLATION
Petersen, P., GODTFREDSEN, J., Boysen, G., Andersen, E. D., & Andersen, B. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91200-2 · Cited by 1,814
Stroke Prevention in Atrial Fibrillation Study. Final results.
Prevention, S., & Atrial Fibrillation Investigators (1991) · Circulation · doi:10.1161/01.cir.84.2.527 · Cited by 1,696
Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial
Mant, J., Hobbs, F. R., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y., & Murray, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61233-1 · Cited by 1,556
The Effect of Low-Dose Warfarin on the Risk of Stroke in Patients with Nonrheumatic Atrial Fibrillation
The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators* (1990) · New England Journal of Medicine · doi:10.1056/nejm199011293232201 · Cited by 1,525
ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation—Executive Summary
Fuster, V., Rydén, L., Cannom, D. S., Crijns, H. J. G. M., Curtis, A. B., Ellenbogen, K. A., Halperin, J. L., Heuzey, J. L., Kay, G. N., Lowe, J. E., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.009 · Cited by 1,161
Canadian atrial fibrillation anticoaguiation (CAFA) study
Connolly, S. J., Laupacis, A., Gent, M., Roberts, R. S., Cairns, J. A., & Joyner, C. D. (1991) · Journal of the American College of Cardiology · doi:10.1016/0735-1097(91)90585-w · Cited by 1,109

Flagged first, then by citations

Show all 45 references

Sorted by citations

Items 701–800 of 853

Antiagregación plaquetaria dual en enfermedad coronaria
Vásquez, S. H., Vesga, B., & Hernández, H. J. (2017) · Revista Colombiana de Cardiología · doi:10.1016/j.rccar.2017.11.017 · Cited by 1
Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation: The Triple Trouble
Leggio, M., Fusco, A., Severi, P., Lombardi, M., Caldarone, E., D’Emidio, S., Armeni, M., Mereu, D., Bendini, M. G., & Mazza, A. (2018) · Drugs · doi:10.1007/s40265-018-0957-8 · Cited by 1
Anticoagulants oraux chez le sujet âgé coronarien en fibrillation atriale
Gallet, R., & Teíger, E. (2018) · Annales de Cardiologie et d Angéiologie · doi:10.1016/j.ancard.2018.09.013 · Cited by 1
Orale Antikoagulation und antithrombozytäre Therapie bei Patienten mit Vorhofflimmern nach Koronarintervention
Schäfer, A., & Bauersachs, J. K. (2019) · Herz · doi:10.1007/s00059-019-4811-x · Cited by 1
Efficacy and safety of direct oral anticoagulants and warfarin in atrial fibrillation patients as part of multicomponent antithrombotic therapy
Николаевна, К. Е., Станиславовна, К. Е., Панченко, Е. П., Zemlianskaia, O., & Samko, A. N. (2020) · Russian Cardiology Bulletin · doi:10.36396/ms.2020.81.60.007 · Cited by 1
Subanalysis of the AUGUSTUS trial
Pavlova, T. V., Дмитриевна, Д. П., Shkaeva, O. V., & Кривова, С. П. (2020) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2020-4104 · Cited by 1
Antithrombotic Management for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Panov, A. V. (2021) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2021-07-02 · Cited by 1
Triple antithrombotic therapy and dual therapy – What is the evidence base?
Essa, H., Sankaranarayanan, R., & Walker, L. E. (2022) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.15257 · Cited by 1
“However, it is well recognised that the bleeding risk increases dramatically as the number of antithrombotic agents increases.(2,9) Efforts to quantify this risk have found that the incidence of all major bleeding per 100 patient-years was 2.”
Background
Atrial Fibrillation
Johnson, K. M., & Cornia, P. B. (2019) · Springer eBooks · doi:10.1007/978-3-030-19704-9_9 · Cited by 1
Combined anticoagulation and antiplatelet therapy in AF patients: why do we not follow guidelines?
Brandes, A. (2014) · Heart · doi:10.1136/heartjnl-2014-306315 · Cited by 1
Comparação entre coronariografia efectuada via artéria radial e via artéria femoral
Luís, S. I. F. (2011) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · Cited by 1
A Systematic Approach to Stroke Prevention for Patients with Atrial Fibrillation
Bungard, T. J., Bucci, C., Kertland, H. R., Leblanc, K., Pickering, J., & Semchuk, W. (2011) · Canadian Pharmacists Journal / Revue des Pharmaciens du Canada · doi:10.3821/1913-701x-144.6.287 · Cited by 1
“, ASA plus clopidogrel) or the use of one or more antiplatelet agents in conjunction with anticoagulant therapy will further increase the risk of major bleeding.(14,15,18) Among patients with atrial fibrillation who had been discharged from hospital with a FIGURE 1 CHADS 2 and CHA 2 DS 2 -VASc scoring systems: Use in…”
Method
Atrial fibrillation and coronary artery disease
Lamberts, M., Dewilde, W., & Hansen, M. L. (2014) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000106 · Cited by 1
“Two large population-based studies, in atrial fibrillation and MI populations including more than 100 000 patients, investigated serious bleeding that required hospitalization [4,5].”
Background
The Triple Challenge of Triple Therapy
Collet, J., Guedeney, P., & Montalescot, G. (2016) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2016.07.016 · Cited by 1
Erratum zu: Thrombozytenaggregationshemmer bei koronarer, zerebraler und peripherer Makroangiopathie. Was, wann, wie lange?
Halbach, M., & Baldus, S. E. (2018) · Der Internist · doi:10.1007/s00108-018-0461-y · Cited by 1
Choosing antithrombotics for atrial fibrillation in primary care
Mustafa, M., & Sheppard, J. P. (2020) · British Journal of General Practice · doi:10.3399/bjgp20x708317 · Cited by 1
Current Stroke Clinical Outcomes of Direct Anticoagulation Therapy in Patients with Valvular Atrial Fibrillation: A Scoping ReviewPreprint
Dabhi, N., Chu, L., Roach, N., & Chapman, S. (2023) · medRxiv · doi:10.1101/2023.02.25.23286281 · Cited by 1
Grenzentscheidungen in der Schlaganfalltherapie
Endres, M., Grond, M., Hacke, W., Ebinger, M., Schellinger, P. D., & Dichgans, M. (2011) · Der Nervenarzt · doi:10.1007/s00115-011-3259-x
Conundrums for Atrial Fibrillation Management in Older Adults
Fanaroff, A. C., & Wang, T. Y. (2015) · Current Geriatrics Reports · doi:10.1007/s13670-015-0143-8
Antithrombotic Therapy in ST‐Segment Elevation Myocardial Infarction
Huber, K., Caterina, R. D., & Kristensen, S. D. (2012) · doi:10.1002/9781118410875.ch14
Trattamento del paziente con sindrome coronarica acuta in età avanzata e con copatologie. “Quando il gioco si fa duro…”
Ferri, L., Bassanelli, G., Morici, N., Luca, L. D., Servi, S. D., & Savonitto, S. (2015) · Recenti Progressi in Medicina · doi:10.1701/2032.22082
Editor's Correspondence
(2011) · Archives of Internal Medicine · doi:10.1001/archinternmed.2011.148
SDH with Bleeding Diathesis—a Management Protocol
Sawhney, G. S., Ross, C. R., Chhabra, M. S., Varghese, V. K., Tiwari, A., & Chand, A. K. (2015) · Indian Journal of Surgery · doi:10.1007/s12262-015-1331-7
“These patients have an increased tendency of rebleed after any surgical procedure more so in a cranial surgery [1, 2].”
Background
Left atrial appendage closure in the warfarin‐intolerant patient
Henrikson, C. A., & Cigarroa, J. E. (2014) · Catheterization and Cardiovascular Interventions · doi:10.1002/ccd.25439
“The use of aspirin in addition to warfarin is a know risk factor for increased bleeding [2].”
Background
Plättchenhemmung und Antikoagulation beim akuten Koronarsyndrom
de Waha, S., Thiele, H., & Richardt, G. (2014) · Herz · doi:10.1007/s00059-014-4132-z
The place of newer oral anticoagulants in the treatment of patients with non-valvular atrial fibrillation and coronary artery disease
McCormack, T. (2013) · International Journal of Clinical Practice · doi:10.1111/ijcp.12165
Fibrillation atriale et infarctus du myocarde : un risque accru de mortalité
Jabre, P., Empana, J. P., & Jouven, X. (2013) · Archives of Cardiovascular Diseases Supplements · doi:10.1016/s1878-6480(13)70884-x
Adding aspirin to clopidogrel worsened outcomes in PCI patients receiving oral anticoagulants
Brott, B. C. (2013) · Annals of Internal Medicine · doi:10.7326/0003-4819-158-12-201306180-02006
Rapport bénéfice–risque de l’association anticoagulants oraux et antiagrégants plaquettaires chez le sujet âgé : revue de la littérature
Omrani, S., Brutel, A., Faure, R., Bourguignon, L., Guilhermet, Y., & Mouchoux, C. (2013) · Le Pharmacien Hospitalier et Clinicien · doi:10.1016/j.phclin.2013.05.007
Management of patients with atrial fibrillation at high risk of stroke: current treatment options
Edwards, D. (2012) · Research Reports in Clinical Cardiology · doi:10.2147/rrcc.s16754
“There is good evidence that warfarin is at least as effective as aspirin in preventing vascular events following myocardial infarction,(39) while the Danish cohort demonstrated a doubled risk of bleeding in patients on aspirin and warfarin dual therapy, and a more than three-fold risk in patients on clopidogrel-warfar…”
Stroke and Bleeding Risks in Patients with Atrial Fibrillation
Maan, A., Ruskin, J. N., & Heist, E. K. (2014) · Interventional Cardiology Clinics · doi:10.1016/j.iccl.2013.11.001
InforMatrix: ADP antagonists in acute coronary syndromes
Janknegt, R., Ruiters, L. A. W., & Cate, H. T. (2012) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2012.651460
“Combined treatment of clopidogrel, ASA and oral anticoagulants results in an increased risk of bleeding [110].”
Background
Post-PCI Antithrombotic Therapy in Patients Requiring Long-Term Anticoagulation
Madhavan, M. V., & Kirtane, A. J. (2015) · Current Cardiology Reports · doi:10.1007/s11886-015-0598-4
Antiplatelet therapy after coronary stent placement in patients with atrial fibrillation
Jovin, I. S. (2014) · Interventional Cardiology · doi:10.2217/ica.14.19
Anti-thrombotic treatment in patients with a long-term indication for anticoagulant therapy undergoing coronary stenting
(GrAM), G. D. A. M., Fiorelli, E. M., & Bonzi, M. (2013) · Internal and Emergency Medicine · doi:10.1007/s11739-013-0951-9
“The association of OAC and antiplatelet agents leads to an increased risk of fatal and non-fatal bleeding events [5]; in particular triple therapy (OAC ? aspirin and clopidogrel) is associated with a prevalence of 12-months major bleeding of 7.”
Background
Triple Antithrombotic Therapy After Coronary Stenting
Verheugt, F. W. A. (2011) · Circulation Cardiovascular Interventions · doi:10.1161/circinterventions.111.965210
Highlights from the IV International Symposium of Thrombosis and Anticoagulation (ISTA), October 20–21, 2011, Salvador, Bahia, Brazil
Lópes, R. D., Becker, R. C., Newby, L. K., Peterson, E. D., Hylek, E. M., Granger, C. B., Crowther, M. A., Wang, T. S., Carvalho, A. C., Berwanger, O. B., et al. (2012) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-012-0700-3
Redemption by RE-DEEM?
Moser, M., & Bode, C. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr051
“This has resulted in excessive bleeding (triple therapy).(4) Thus, long-term anticoagulation therapy”
Background
Étude WOEST : Utilisation du clopidrogrel avec ou sans acide acétylsalicylique pour les patients anticoagulés subissant une intervention coronarienne percutanée
Beauchemin, M., Bystrzycki, M., & Richer, C. (2015) · Pharmactuel
Novel Oral Anticoagulants for Stroke Prevention in Patients with Non-valvular Atrial Fibrillation
Rozenman, Y., & Gluzman, Y. (2013) · Springer eBooks · doi:10.1007/978-1-4471-5475-4_3
Antikoagulation während und nach perkutanen Koronarinterventionen: Update 2013
Höchtl, T., & Huber, K. (2013) · Journal für Kardiologie (Krause & Pachernegg GmbH)
Adherence to INR monitoring in the community among VKA-treated patients in Saskatchewan : an observational study
Boyko, J. A. (2014) · University Library - University of Saskatchewan (University of Saskatchewan)
Research Highlights: Highlights from the latest articles in antithrombotic and myocardial revascularization strategies in coronary artery disease
Kassimis, G., & BANNING, A. P. (2013) · Interventional Cardiology · doi:10.2217/ica.13.18
Practice Guidelines Chest Physicians Evidence-Based Clinical Thrombosis, 9th ed: American College of : Antithrombotic Therapy and Prevention of Antithrombotic Therapy for Atrial Fibrillation
Halperin, J. L., Lip, G. Y. H., Hughes, M., Spencer, F. A., Manning, W. J., Eckman, H., Fang, M. C., Hylek, E. M., Schulman, S., Singer, D. E., et al. (2012)
The Use of Warfarin in Atrial Fibrillation
Rifkin, E., & Lazris, A. (2014) · Springer eBooks · doi:10.1007/978-3-319-11544-3_12
Traitements antiplaquettaire et anticoagulant des syndromes coronariens aigus
Nallet, O., Pascal, J., & Millischer, D. (2016) · Réanimation · doi:10.1007/s13546-016-1177-4
“Comparée à la DAP, la trithérapie (DAP et anticoagulant oral) multiplie par 2 à 3 l’incidence des complications hémorragiques [57].”
Background
Indicaciones y duración de las combinaciones de antiagregantes
Quiles, J., & Rodríguez-Manteca, M. (2016) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2015.05.006
CONTEMPORARY APPROACHES TO ANTIPLATELET THERAPY IN CORONARY HEART DISEASE TREATMENT
Мацкеплишвили, С. Т., & Arutyunova, S. Y. (2014) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2014-4-69-74
Grupo de Trabajo de Revascularización Miocárdica de la Sociedad Europea de Cardiología (ESC) y la European Association for Cardio-Thoracic Surgery (EACTS) Desarrollada con la colaboración especial de la European Association of Percutaneous Cardiovascular Interventions (EAPCI)
Windecker, S. (2016)
H. Vik-Mo svarer:
Vik‐Mo, H. (2011) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.11.0383
Perkutaner Vorhofohrverschluss
Ledwoch, J., Hein-Rothweiler, R., & Mudra, H. G. (2014) · Der Kardiologe · doi:10.1007/s12181-014-0617-5
Wytyczne ESC dotyczące postępowania w ostrym zawale serca z przetrwałym uniesieniem odcinka ST Grupa Robocza Europejskiego Towarzystwa Kardiologicznego (ESC) do spraw postępowania w ostrym zawale serca z uniesieniem odcinka ST
James, S. K. (2012)
Triple Antithrombotic Therapy: Is it Time to Drop the Aspirin?
Papadimitriou, P. (2015)
Systematic Review/Meta-analysis Risk of Bleeding on Triple Antithrombotic Therapy After Percutaneous Coronary Intervention/Stenting: A Systematic Review and Meta-analysis
Andrade, J. G., Deyell, M. W., Khoo, C., & Cairns, J. A. (2013)
Triple Oral Antithrombotic Therapy
Nouri, S. N., & Block, B. L. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.4415
Anticoagulation for Atrial Fibrillation and Prosthetic Cardiac Valves
DeLoughery, T. G. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-2296-9.00047-6
Bloedverdunning anno 2016
Willemsen, R. T. A., Dinant, G., Verheugt, F. W. A., Cate, H. T., & Weerkamp Nico, J. (2016) · Huisarts en Wetenschap · doi:10.1007/s12445-016-0187-9
Practice Variation in Patients Eligible for Triple Therapy
Vora, A. N., & Patel, M. R. (2015) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2015.12.003
Iatrogenic hemorrhagic strokes: intracranial bleeding
Tsiskaridze, A., Lindgren, A. G., & Qureshi, A. I. (2016) · Cambridge University Press eBooks · doi:10.1017/cbo9781139775397.018
Dual Antiplatelet Therapy and Anticoagulation in Patients Post Percutaenous Coronary Intervention
Rashid, S. (2016) · Archives of Medicine · doi:10.21767/1989-5216.1000160
“Bleeding risk was therefore three times higher with dual or triple therapy for AF when compared to warfarin alone [5].”
Background
Original Article Subtle renal dysfunction and bleeding risk in atrial fibrillation: symmetric dimethylarginine predicts HAS-BLED score
Procter, N. E. K., Ball, J., Heresztyn, T., Nooney, V. B., Liu, S., Chong, C., Isenberg, J. S., Chirkov, Y. Y., Stewart, S., Horowitz, J. D., et al. (2015)
Das Vorhofflimmern ist eine komplexe Herausforderung
Stiefelhagen, P. (2016) · CME · doi:10.1007/s11298-016-5744-9
Bioresorbable scaffold implantation in patients with indication for oral anticoagulation: A propensity matched analysis
Boeder, N., Johnson, V., Dörr, O., Wiebe, J., Elsässer, A., Möllmann, H., Hamm, C. W., NEF, H. M., & Bauer, T. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.11.280
“TAT, however, has a higher bleeding risk [7], and ultimately hemorrhagic complications might offset all ischemic benefits [8].”
Background
The relationship between non-steroid anti-inflammatory drugs and cardiovascular risk - the myths, the misconceptions, the news, the realities -
Stoia, M. A. (2015) · Balneo Research Journal · doi:10.12680/balneo.2015.1110
Atrial Fibrillation on Vitamin K Antagonist Oral Anticoagulant Undergoing Primary Percutaneous Coronary Intervention for ST-Elevation Acute Myocardial Infarction
Kiviniemi, T., & Airaksinen, J. K. E. (2016) · Springer eBooks · doi:10.1007/978-3-319-42400-2_6
Stroke and the heart : a focus on atrial fibrillation and heart failure
Abdul‐Rahim, A. H. (2017) · Enlighten: Theses (The University of Glasgow)
Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation
Stærk, L., Jonas, B., & Jannik, L. (2016)
LONG-TERM ANTICOAGULATION THERAPY IN SECONDARY PREVENTION OF ACUTE CORONARY SYNDROME: HOW TO CHOOSE THE PATIENT?
Komarov, A. L. (2016) · Aterotromboz = Atherothrombosis · doi:10.21518/2307-1109-2016-1-26-38
Atrial fibrillation, bleeding, and coronary intervention
Farhan, S., & Mehran, R. (2017) · Coronary Artery Disease · doi:10.1097/mca.0000000000000549
Antithrombotische Therapie bei Vorhofflimmern und perkutaner Koronarintervention/akutem Koronarsyndrom
Olivier, C. B., Bode, C., & Moser, M. (2017) · Aktuelle Kardiologie · doi:10.1055/s-0043-120291
“Die aus dieser Überlegung resultierende „Triple-Therapie“ (TT) (DAPT + OAK) geht allerdings mit einem hohen Blutungsrisiko einher [18].”
Background
Is the Risk of Bleeding Among Older Adults With Atrial Fibrillation Lower With Antiplatelet Compared With Oral Anticoagulants?
Gettel, C. J., & Goldberg, E. M. (2017) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2017.10.011
Update On the Use of Direct Oral Anticoagulants for the Prevention and Treatment of Thromboembolism
Jacobs, A. R., Kabra, R., Das, P., & Oliphant, C. S. (2017) · Future Cardiology · doi:10.2217/fca-2017-0045
Risk of Bleeding and Effect of Stroke Prevention Between Warfarin Single Therapy and Warfarin-Aspirin Combination Therapy in Patients with Atrial Fibrillation
박지은, 서인아, 석현주, 안지현, 손은선, 김성은, 이정은, & 고종희 (2013) · Journal of Korean Society of Health-System Pharmacists · doi:10.32429/jkshp.2013.30.1.004
The outcomes of clopidogrel therapy in patients with ACS in southern Tasmania
Vonna, A. (2013) · UTAS Research Repository · doi:10.25959/23208047
Overview of Anticoagulation Agents
Jorshery, S. D., Aurshina, A., & Chaar, C. I. O. (2017) · Springer eBooks · doi:10.1007/978-3-319-65226-9_21
Does Rivaroxaban Better than Vitamin K Antagonists in Atrial Fibrillation Patients Undergoing PCI?
Kara, M., Mokhtar, O. A., Azaza, A., Seddiki, S., & Harbi, F. (2016) · Archives of Hematology Case Reports and Reviews · doi:10.17352/ahcrr.000003
Anticoagulation et antiagrégation: marche à suivre péri-interventionnelle
Nagler, M., Erné, P., Babst, R., Korte, W., & Wuillemin, W. A. (2011) · Forum Médical Suisse ‒ Swiss Medical Forum · doi:10.4414/fms.2011.07539
Antithrombotic management in the acute coronary syndrome setting
Rubboli, A. (2012) · doi:10.2217/ebo.12.42
Pharmacological stroke prevention: antithrombotic drugs
Weimar, C., & Weber, R. (2012) · doi:10.2217/ebo.12.58
Antithromboembolic Strategies for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention
Ather, A., Laliberte, B., Reed, B. N., Schenk, A., Watson, K., Devabhakthuni, S., & See, V. Y. (2018) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-018-0287-y
Novel Oral Anticoagulants (NOACs) Roundtable – Hot Topics and Current Issues in association with Arrhythmia & Electrophysiology Review
Camm, A. J., Alings, M., Caterina, R. D., Kirchhof, P. F., Heuzey, J. L., Verheugt, F. W. A., & Onze Lieve Vrouwe Gasthuis, A. (2015) · Arrhythmia & Electrophysiology Review · doi:10.15420/aer.2015.4.1.sup1
“There is uncertainty over the optimal antithrombotic management strategy for patients with AF presenting with an acute coronary syndrome and/or undergoing percutaneous coronary intervention (PCI)/stenting.(36) Professor De Caterina showed that 8–10 % of AF patients of cardiology departments develop ACS or need electiv…”
Background
Clinical Characteristics, Procedural Factors, and Outcomes of Percutaneous Coronary Intervention in Patients With Mechanical and Bioprosthetic Heart Valves.
Gajanana, D., Rogers, T., Weintraub, W., Iantorno, M., Buchanan, K. D., Ben-Dor, I., Pichard, A., Satler, L., Thourani, V., Torguson, R., et al. (2018) · American Journal of Cardiology · doi:10.1016/j.amjcard.2018.07.026 · Cited by 1
Antithrombotic Treatment in Patients Undergoing Transcatheter Aortic Valve Replacement
Asher, E., & Segev, A. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-812615-8.00043-0
Novel Oral Anticoagulants (NOACs) Roundtable – Hot Topics And Current Issues
Mountfort, K. A. (2015) · Arrhythmia & Electrophysiology Review · doi:10.15420/aer.2015.4.1.s1
Acute coronary syndrome : bleeding, platelets and gender
Holm, A. (2019) · Linköping University medical dissertations · doi:10.3384/diss.diva-153621
Warfarin and other vitamin K antagonists
Stein, P. D. (2016) · Wiley eBooks · doi:10.1002/9781119039112.ch104
Optimizing Anticoagulation in Older Patients with Nonvalvular Atrial Fibrillation
Te, A. L. D., Chao, T., & Chen, S. (2019) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-019-0599-8
Venous Thromboembolic Disease in Older Adults
Shcherba, M., Billett, H. H., & Jacobs, L. G. (2013) · doi:10.1201/b15156-32
Kombinierte antithrombotische Therapiestrategien in der Kardiologie
Moser, M. (2019) · Kardiologie up2date · doi:10.1055/a-0720-1003
“Kardiologie up2date 20 und Antikoagulation in jeweils unveränderter Intensität zu einer inakzeptabel hohen Blutungsrate führte [22].”
Background
Antiplatelet Drugs in the Management of Coronary Artery Disease
Moon, J. Y., & Angiolillo, D. J. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-813456-6.00056-4
Possibility of using dabigatran in patients with atrial fibrillation and acute coronary syndrome and PCI
Erlich, A. D. (2019) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2019-5-30-35
Hematological Management of Neurocritical Care Patients
Tadevosyan, A., Navarro, J. C., Rasheed, I.-Y. D., & Kumar, M. A. (2019) · Springer eBooks · doi:10.1007/978-981-13-3390-3_16
Antithrombotic Strategy in Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention
Kwak, S., & Yang, H.-M. (2019) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2019.8.1.8
Does dual vs. triple antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation lower the risk of bleeding at the cost of increased risk of ischemic events?
Gupta, K., Prejean, S. P., Vaduganathan, M., Golwala, H. B., Watts, T. E., Aryal, S. R., Mering, G. V., Booker, O. J., Ahmed, M. I., & Bajaj, N. S. (2019) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2019.100404
Safe and Efficacious Use of 1-Month Triple Therapy in Patients with Atrial Fibrillation and High Bleeding Risk Undergoing PCI
Sambola, A., Bueno, H., Miranda, B., Hernández, A. V., Freire, J. L., del Blanco, B. G., & García‐Dorado, D. (2019) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-019-06889-7
Novel Approach of Antithrombotic Potency Amongst Patients Admitted to Hospital with Bleeding Using HEMORR2HAGES Score: A Retrospective Cohort Study
Alshibani, M. (2019) · The Heart Surgery Forum · doi:10.1532/hsf.2645
Fatores sociodemográficos, clínicos e a prevenção secundária do acidente vascular cerebral: análise transversal na linha de base do Estudo Longitudinal de Saúde do Adulto (ELSA-Brasil)
de Abreu, F. G. (2019) · doi:10.11606/d.5.2019.tde-14112019-153710
Prediction of the Possibility of Hemorrhagic Syndrome during Combined Antiplatelet Therapy According to the Krasnodar Region Registry
Татаринцева, З. Г., Kosmacheva, E. D., Кручинова, С. В., Akinshina, V. A., & Khalafyan, A. A. (2019) · Rational Pharmacotherapy in Cardiology · doi:10.20996/1819-6446-2019-15-5-697-705
Evaluation of the effect of direct oral anticoagulant availability on hospital presentations for bleeding related to oral anticoagulation in South Australia
Roberts, G., Chong, C., Quinn, S. J., Cameron‐Collins, S., Forbes, H. L., Johnson, J. L., Kitto, L., Marotti, S. B., Nguyen, H., Reid, S., et al. (2019) · Journal of Pharmacy Practice and Research · doi:10.1002/jppr.1567
Complex management of atrial fibrillation
Kalich, B. A. (2019) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1186

Authors: Hansen, M. L., Sørensen, R., Clausen, M. T., Fog-Petersen, M. L., Raunsø, J., Gadsbøll, N., Gislason, G. H., Folke, F., Andersen, S. S., Schramm, T. K., Abildstrøm, S. Z., Poulsen, H. E., Køber, L., & Torp-Pedersen, C.
Affiliations: Copenhagen University Hospital (DK)
ORCID: Hansen, Morten L.
Sørensen, Rikke
Raunsø, Jakob
Gislason, Gunnar H.
Folke, Fredrik
Poulsen, Henrik E.
Køber, Lars
Torp-Pedersen, Christian
Venue: Archives of Internal Medicine
Publisher: American Medical Association (AMA)
Published: 2010-09-13
Volume: 170
Issue: 16
Pages: 1433-41
ISSN: 0003-9926 (ISSN-L)
DOI: 10.1001/archinternmed.2010.271
OpenAlex: W2144471064
Cited by: 855
References: 45
Citations by year: 2026: 16 · 2025: 23 · 2024: 23 · 2023: 25 · 2022: 41 · 2021: 37 · 2020: 64 · 2019: 83 · 2018: 63 · 2017: 75 · 2016: 80 · 2015: 68 · 2014: 63 · 2013: 76 · 2012: 63
FWCI: 42.19
Type: journal article
Language: en
Open access: closed
Locations: Archives of Internal Medicine (publishedVersion)
PubMed (publishedVersion)
Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
Keywords: atrial fibrillation, bleeding risk, warfarin, aspirin, clopidogrel, combination antithrombotic therapy, triple therapy, dual therapy, anticoagulation, platelet aggregation inhibition, fatal bleeding
MeSH terms: Clopidogrel, Aged, Anticoagulants, Aspirin, Atrial Fibrillation, Brain Ischemia, Denmark, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Registries, Risk, Ticlopidine, Warfarin, Cohort Studies, Comorbidity, Incidence, Proportional Hazards Models, Stroke

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Risk of Bleeding With Single, Dual, or Triple Therapy With Warfarin, Aspirin, and Clopidogrel in Patients With Atrial Fibrillation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks